1. Soft nanoparticles as antimicrobial agents and carriers of microbiocides for enhanced inhibition activity.
- Author
-
Yong HW, Ojagh SMA, Théberge-Julien G, Castellanos LSR, Tebbji F, van de Ven TGM, Sellam A, Rhéaume É, Tardif JC, and Kakkar A
- Subjects
- Particle Size, Micelles, Curcumin pharmacology, Curcumin chemistry, Humans, Nanoparticles chemistry, Escherichia coli drug effects, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents chemical synthesis, Microbial Sensitivity Tests, Drug Carriers chemistry, Bacillus subtilis drug effects
- Abstract
Antibiotic resistance continues to pose significant health challenges. Considering severe limitations in the discovery and supply of new antibiotics, there is an unmet need to design alternative and more effective strategies for addressing this global issue. Use of polymeric nanoparticles with cationic shell surfaces offers a highly promising approach to coupling their inherent bactericidal action with sustained delivery of small lipophilic microbicides. We have utilized this platform for assembling multi-tasking soft core-shell nanoparticles from star polymers with the desired asymmetric arm composition. These stable nanoparticles with low critical micelle concentration imparted intrinsic antimicrobial potency due to high positive charge density in the corona, as well as the loading of active biocidal agents (such as curcumin and terbinafine) for potential dual and coadjuvant inhibition. This strategic combination allows for both immediate (direct contact) and extended (drug delivery) antibacterial activities for better therapeutic efficacy. Micellar nanoparticles with and without therapeutic cargo were highly efficient against both Escherichia coli ( E. coli ) and Bacillus subtilis ( B. subtilis ), representative Gram-negative and Gram-positive bacteria, respectively. Interestingly, we observed bacteria- and concentration-dependent effects, in which higher concentrations of charged nanoparticles were more effective against E. coli , whereas B. subtilis was inhibited only at lower concentrations. This work highlights a valuable platform to achieve combination therapy through nanoparticles with charged coronas and delivery of potent therapeutics to overcome antimicrobial resistance.
- Published
- 2024
- Full Text
- View/download PDF